|
Lynda Schneider is engaged in evaluating new therapies for allergic diseases through clinical trials. Current trials focus on evaluating a multidisciplinary approach to caring for children with atopic dermatitis (AD), exploring the genetics and phenotypes of patients with AD, and evaluating prophylactic treatments for asthma.
Through the 1990s Dr. Schneider and colleagues evaluated new treatments for atopic dermatitis, including interferon-gamma, topical tacrolimus, and pimecrolimus. They also studied the use of anti-IgE for food allergy and C1-inhibitor for hereditary angioedema. Other projects have included the use of intravenous immunoglobulin for asthma as well as anti-IgE for asthma.
Her current projects include the Study Atopic March project which evaluates early intervention for babies with atopic dermatitis to see if the development of asthma and other allergic diseases can be modified. Children's Hospital Boston has been funded by the National Institutes of Health as a site for the Atopic Dermatitis and Vaccinia Network: Clinical Studies Consortium.
|
